688606 Hangzhou Alltest Biotech
- 67.48
- -1.08-1.58%
Hangzhou Alltest Biotech News
Some Investors May Be Worried About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that,
Aotai Biotech (688606.SH)'s net profit of 44.79 million yuan in the first quarter increased 10.50% year-on-year
Gelonghui, April 26 | Aotai Biotech (688606.SH) announced that in the first quarter of 2024, the company's revenue was 200 million yuan, a year-on-year decrease of 15.34%; net profit attributable to shareholders of listed companies was 44.79 million yuan, an increase of 10.50% over the previous year; and basic earnings per share were 0.56 yuan/share.
Revenues Not Telling The Story For Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606)
It's not a stretch to say that Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) price-to-sales (or "P/S") ratio of 6.5x seems quite "middle-of-the-road" for Medical Equipment companies in China, se
Express News | Huahai Pharmaceutical: The subsidiary's key phase III clinical trial of HB0017 (IL-17A monoclonal antibody) injection ushered in the first case of the test subject
Aotai Biotech (688606.SH): The ban on 2.092,900 restricted shares was lifted on March 25
Gelonghui March 14 | Aotai Biotech (688606.SH) announced that the total number of shares in circulation during the current stock listing of the company is 2.092,900 shares. The stock listing and circulation date is March 25, 2024.
Is Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Stock Price Struggling As A Result Of Its Mixed Financials?
With its stock down 20% over the past three months, it is easy to disregard Hangzhou Alltest Biotech (SHSE:688606). It is possible that the markets have ignored the company's differing financials an
Aotai Biotech (688606.SH) completed the repurchase and spent 595.75,500 yuan to repurchase 1.03 million shares
Aotai Biotech (688606.SH) announced that the company has completed the repurchase and has actually repurchased 1.03 million shares of the company's shares, accounting for...
Aotai Biotech (688606.SH)'s net profit for 2023 was 180 million yuan, a sharp decrease of 84.8%
Aotai Biotech (688606.SH) disclosed the 2023 annual results report, and the company achieved a total operating revenue of 7.55...
Aotai Biotech (688606.SH): It spent 53.432 million yuan to buy back a total of 1.1651% of the shares
Gelonghui, January 31, 丨 Aotai Biotech (688606.SH) announced that as of January 31, 2024, the company had repurchased a total of 923,700 shares of the company's shares through centralized bidding transactions, accounting for 1.1651% of the company's total share capital of 79,280,855 shares, an increase of 0.6606% compared with the previous disclosure. The highest price of the repurchase transaction was 60.00 yuan/share, the lowest price was 55.11 yuan/share, and the total capital paid was RMB 53.432 million (excluding stamp duty, transaction commissions, etc.) transaction fees).
Aotai Biotech (688606.SH): Net profit is expected to drop 85.23% year on year to 86.07% in 2023
Gelonghui, January 26丨Aotai Biotech (688606.SH) announced that according to preliminary estimates by the financial department, Hangzhou Aotai Biotechnology Co., Ltd. is expected to achieve operating income of 747 million yuan to 757 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will decrease 2631.57 million yuan to 2641.57 million yuan, a year-on-year decrease of 77.66% to 77.96%. In 2023, net profit attributable to owners of the parent company is expected to reach 165 million yuan to 175 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will
Xianju Pharmaceutical: Aotai Biotech plans to transfer 16% of Hangzhou Visbo's shares in the subsidiary for 16 million yuan
Gelonghui, January 5 | Xianju Pharmaceutical announced that the holding subsidiary Zhejiang Bai'an Medical Technology Co., Ltd. listed to transfer 16% of its shares in Hangzhou Visbo Medical Technology Co., Ltd., and Hangzhou Aotai Biotechnology Co., Ltd. became the intended transferee of 16% of Hangzhou Visbo's shares.
Aotai Biotech (688606.SH): A total cost of 22.64 million yuan to buy back 0.5% of shares
Gelonghui, January 2, 丨 Aotai Biotech (688606.SH) announced that as of December 31, 2023, the company had repurchased 400,000 shares of the company's shares through centralized bidding transactions, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest price of the repurchase transaction was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22,641,640.33.
Aotai Biotech (688606.SH): Repurchased 400,000 shares at a total cost of 22.64 million yuan
Gelonghui (688606.SH) announced on November 1 | Aotai Biotech () announced that as of October 31, 2023, the company has repurchased a total of 400,000 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase transaction price is 58.01 yuan/share, the lowest price is 55.11 yuan/share, and the total capital paid is RMB 22,641,640.33.
Aotai Biotech (688606.SH): A total of 400,000 shares have been repurchased by the end of September
Glonghui, October 10, 丨 Aotai Biotech (688606.SH) announced that as of September 30, 2023, the company had repurchased 400,000 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase price was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22,641,640.33 (excluding transaction fees such as stamp duty and transaction fees).
Aotai Biotech (688606.SH): At a cost of 22.641,600 yuan, a total of 400,000 shares have been repurchased
Glonghui September 27丨Aotai Biotech (688606.SH) announced that as of the close of trading on September 27, 2023, the company had repurchased 400,000 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase price was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22.641,600 (excluding transaction fees such as stamp duty and transaction fees).
Aotai Biotech (688606.SH): The company has not implemented a share repurchase
Glonghui September 4 丨 Aotai Biotech (688606.SH) announced that as of August 31, 2023, the company has not implemented a share repurchase.
Aotai Biotech (688606.SH) released semi-annual results, net profit of 71.18 million yuan, a year-on-year decrease of 94.54%
Aotai Biotech (688606.SH) disclosed the 2023 semi-annual report. The company achieved revenue of 3.88 during the reporting period...
The controlling shareholder of Aotai Biotech (688606.SH) proposed to spend 42 million yuan to 60 million yuan to buy back the shares
Aotai Biotech (688606.SH) announced that the company received actual control from the company's controlling shareholder on August 16...
Aotai Biotech (688606.SH): Fentanyl urine detection reagent obtained 510K certification from the US FDA
According to the Zhitong Finance App, Aotai Biotech (688606.SH) announced that the company has received a notice from the U.S. Food and Drug Administration (“FDA”) that the company's fentanyl urine test reagent has obtained 510K certification from the US FDA. The fentanyl urine detection reagent that obtained 510K certification from the US FDA this time is a rapid detection reagent independently developed by the company to qualitatively detect fentanyl in human urine. The detection threshold is 1 ng/ml. The product is easy to operate, no instruments required
Lu Weike, director of Aotai Biotech (688606.SH), has not reduced his holdings at the end of the holdings reduction period
According to the Zhitong Finance App, Aotai Biotech (688606.SH) announced that Lu Wei, the company's director, senior manager, and core technician, has reduced his holdings of the company by a total of 0 shares, accounting for 0% of the company's total share capital. As of the disclosure date of this announcement, the time period for the current holdings reduction plan has expired.
Analysis
Price Target
No Data
